Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3

Vyome Holdings, Inc

Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.
No FDA-approved therapies for malignant fungating wounds; 56.5% probability of approval assumed.
Peak net sales imply $2.2B TAM in 2026, $2.8B by 2040; 30% market share modeled.
Pricing $20/gram ($9,125/month); Phase 3 starts Q3 2026, NDA and launch targeted Q4 2028.
Development costs to 2028 estimated at $10M; potential partners include BMS and Pierre Fabre.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.